Complete response letter for empagliflozin

Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said FDA issued a complete response letter for an NDA from Boehringer for empagliflozin to treat Type II diabete...